Data from MUK one, the first trial to be conducted through the Myeloma UK Clinical Trial Network (CTN) have been published in the British Journal of Haematology. MUK one, a Phase II multicentre, open label, randomised trial aimed to identify the optimal starting dose of bendamustine when given in combination with thalidomide and dexamethasone in relapsed and/or refractory myeloma patients. The results demonstrated that a dose of 60mg/m2 given twice a month with thalidomide and dexamethasone was tolerable over repeated cycles and showed substantial clinical activity even in heavily pretreated patients. The publication represents a major milestone and marks the completion of the first trial within the CTN.
